The roles of genetic polymorphisms and human immunodeficiency virus infection in lipid metabolism.
The roles of genetic polymorphisms and human immunodeficiency virus infection in lipid metabolism.
复制标题
DOI：
10.1155/2013/836790
复制
发表时间：
2013
影响因子：
--
通讯作者：
Watanabe MA
中科院分区：
文献类型：
--
作者：
de Almeida ER;Reiche EM;Kallaur AP;Flauzino T;Watanabe MA
在人类免疫缺陷病毒1型（HIV-1）感染者中经常观察到血脂异常，与HIV-1、宿主和抗逆转录病毒治疗（ART）相关的因素参与了这一现象。本文综述了基因多态性、HIV-1感染和高效抗逆转录病毒治疗（HAART）在脂代谢中的作用。血脂异常可根据HAART方案而变化，例如蛋白酶抑制剂（PI）。然而，遗传因素也可能参与血脂异常，因为并非所有接受相同HAART方案且具有可比人口统计学、病毒学和免疫学特征的患者都会发生血脂谱变化。大量基因的多态性参与了结构蛋白的合成，与脂质代谢相关的酶解释了每个个体脂质谱的变化。由于某些遗传多态性可能导致血脂异常，因此应在HIV-1感染患者中研究这些等位基因变异，以确定HAART治疗期间（特别是PI治疗期间）发生血脂异常风险增加的个体。这些知识可以指导个体化治疗决策，并导致开发新的治疗靶点，用于治疗这些患者的血脂异常。
Dyslipidemia has been frequently observed among individuals infected with human immunodeficiency virus type 1 (HIV-1), and factors related to HIV-1, the host, and antiretroviral therapy (ART) are involved in this phenomenon. This study reviews the roles of genetic polymorphisms, HIV-1 infection, and highly active antiretroviral therapy (HAART) in lipid metabolism. Lipid abnormalities can vary according to the HAART regimen, such as those with protease inhibitors (PIs). However, genetic factors may also be involved in dyslipidemia because not all patients receiving the same HAART regimen and with comparable demographic, virological, and immunological characteristics develop variations in the lipid profile. Polymorphisms in a large number of genes are involved in the synthesis of structural proteins, and enzymes related to lipid metabolism account for variations in the lipid profile of each individual. As some genetic polymorphisms may cause dyslipidemia, these allele variants should be investigated in HIV-1-infected patients to identify individuals with an increased risk of developing dyslipidemia during treatment with HAART, particularly during therapy with PIs. This knowledge may guide individualized treatment decisions and lead to the development of new therapeutic targets for the treatment of dyslipidemia in these patients.
登录
查看更多内容
影响因子：
5.2
作者：
Calza, L;Manfredi, R;Chiodo, F
通讯作者：
Chiodo, F
DOI：
10.1111/j.1365-2362.1994.tb02185.x
发表时间：
1994-06-01
影响因子：
5.5
作者：
CONSTANS, J;PELLEGRIN, JL;CONRI, C
通讯作者：
CONRI, C
影响因子：
7
作者：
Collins, FS;Brooks, LD;Chakravarti, A
通讯作者：
Chakravarti, A
影响因子：
--
作者：
Barter, PJ
通讯作者：
Barter, PJ
影响因子：
56.9
作者：
BROWN, MS;GOLDSTEIN, JL
通讯作者：
GOLDSTEIN, JL